Gyre Therapeutics, Inc. (GYRE)
- Previous Close
16.33 - Open
16.33 - Bid 16.96 x 100
- Ask 17.13 x 200
- Day's Range
15.90 - 17.25 - 52 Week Range
3.00 - 30.40 - Volume
190,123 - Avg. Volume
79,493 - Market Cap (intraday)
1.526B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
www.gyretx.comRecent News: GYRE
Performance Overview: GYRE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GYRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GYRE
Valuation Measures
Market Cap
1.53B
Enterprise Value
1.49B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.93
Price/Book (mrq)
--
Enterprise Value/Revenue
13.16
Enterprise Value/EBITDA
73.46
Financial Highlights
Profitability and Income Statement
Profit Margin
-81.92%
Return on Assets (ttm)
11.93%
Return on Equity (ttm)
-113.45%
Revenue (ttm)
113.45M
Net Income Avi to Common (ttm)
-92.93M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
33.51M
Total Debt/Equity (mrq)
0.52%
Levered Free Cash Flow (ttm)
20.67M